Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer
Leslie Ballas1, Parminder Singh2, Seth P Lerner3
1Department of Radiation Oncology University of Southern California Keck School of Medicine, Los Angeles, CA.
Urologic Oncology
|November 6, 2020
Abstract:
Radical cystectomy with bilateral pelvic lymphadenectomy and trimodality bladder-sparing therapy or TMT, are both curative options for patients with nonmetastatic muscle invasive bladder cancer. Patients should be afforded the opportunity for a multidisciplinary evaluation with equipoise in discussing these options for eligible patients. We discuss the barriers to broader acceptance and utilization of TMT and encourage support of clinical trials of TMT.
